#USA #New York #Class Action #Faruqi & Faruqi #Skye Biosciences

Faruqi & Faruqi's Reminder: Lead Plaintiff Deadline Approaches for Skye Investors

In an important announcement for investors of Skye Biosciences, Inc., the national securities law firm Faruqi & Faruqi, LLP is reinforcing the urgency of a pending class action lawsuit. The deadline for interested investors to step forward as lead plaintiffs is set for January 16, 2026. This lawsuit arises from allegations that Skye's executives misled investors regarding the effectiveness of their leading product, nimacimab.

Faruqi & Faruqi has a notable history of advocating for investors, having recovered substantial amounts since its inception in 1995. The firm is currently responding to potential claims against Skye and encourages affected investors to reach out to discuss their legal options. For those who purchased or acquired Skye securities between November 4, 2024, and October 3, 2025, this period is particularly relevant. Investors may find themselves eligible for compensation if the allegations are substantiated in court.

The allegations focus on misleading statements made by Skye's executives concerning nimacimab's efficacy. Previously, on October 6, 2025, during the announcement of pivotal data from a Phase 2a CBeyond™ proof-of-concept study, it became evident that the clinical results did not meet the expected outcomes. According to the data released, the nimacimab monotherapy group failed to achieve its primary objective regarding weight loss against placebo. This disappointing news led to a drastic drop in Skye’s stock price—a decline of 60%, closing at $1.90 per share. Such a significant fall underscores the potential damage to investors who relied on the company’s prior claims about the drug's effectiveness.

Faruqi & Faruqi emphasizes the importance of the court-designated lead plaintiff, who plays a critical role in leading the litigation on behalf of the entire class. Interested parties might consider becoming the lead plaintiff or could opt to remain as passive class members without affecting their potential recovery from the lawsuit. Importantly, engagement in the lawsuit does not jeopardize an investor's chances of receiving compensation.

Faruqi & Faruqi continues to encourage anyone with information regarding the conduct of Skye, including whistleblowers and former employees, to come forward. Their insights could be crucial in strengthening the case against Skye. For more information on this class action lawsuit, investors can visit Faruqi & Faruqi’s website or contact their offices directly.

As the January deadline approaches, affected investors are urged to act swiftly to safeguard their rights and explore their options in this evolving situation. This class action could serve as a critical avenue for justice and compensation for those who trusted in the promises made by Skye and its management. Keeping abreast of developments is essential for all stakeholders involved.